Vitamin E Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Vitamin E dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Vitamin E.
Dosing Protocols
Beginner protocol (dietary adequacy). For healthy adults: no routine supplementation required beyond dietary sources. The RDA is 15 mg α-tocopherol equivalents per day (approximately 22 IU of natural RRR-α-tocopherol). Easy dietary targets: 1 oz (28 g) sunflower seeds provides approximately 7 mg α-tocopherol; 1 oz almonds provides 7 mg; 1 tablespoon wheat germ oil provides 20 mg; 1 tablespoon sunflower oil provides 5-6 mg; 1 cup cooked spinach provides 6 mg; 1 medium avocado provides 4 mg; 1 tablespoon olive oil provides 2 mg; 1 cup boiled broccoli provides 2 mg. A varied diet with nuts, seeds, vegetable oils, leafy greens, and whole grains easily delivers the RDA without supplementation. A standard multivitamin providing 15-30 IU α-tocopherol (usually as the dl- synthetic form) is acceptable insurance but not necessary.
For specific populations with deficiency risk: cystic fibrosis, chronic cholestatic liver disease, short bowel syndrome, abetalipoproteinemia, or AVED — specialist-directed supplementation at doses appropriate to the malabsorption or genetic severity. TPGS or water-soluble α-tocopherol formulations are preferred when fat absorption is severely impaired.
For elderly immune support: α-tocopherol 100-200 IU/day is a modest evidence-supported dose (Meydani 2004). Often combined in a basic multivitamin or senior-formulation supplement.
For pregnancy and lactation: maintain dietary adequacy at the 15 mg/day RDA; a standard prenatal vitamin provides this. Do not supplement above RDA without specific obstetric indication.
Intermediate protocol (specific clinical indications). For biopsy-proven NASH in non-diabetic adults: α-tocopherol (natural RRR-α-tocopherol preferred) 800 IU/day in divided doses with meals, under hepatology guidance. Expect histologic improvement at 96 weeks per PIVENS protocol (Sanyal 2010). Monitor LFTs every 3-6 months. Plan for eventual dose reduction or discontinuation given long-term α-tocopherol safety signals. Continue standard NASH management (weight loss, diabetes control where applicable, cardiovascular risk factor optimization). Do not combine with warfarin without close INR monitoring and coagulation risk/benefit discussion.
For mild-to-moderate Alzheimer's disease: α-tocopherol 2,000 IU/day in divided doses with meals (Dysken 2014 TEAM-AD, PMID 24381967). Expect approximately 6 months delayed functional decline over 2-3 years. Monitor for bleeding complications, particularly in patients on concurrent anticoagulants or antiplatelet drugs. Pair with vitamin K2 MK-7 180-360 μg/day to offset γ-carboxylation impairment. Continue standard dementia care (cholinesterase inhibitor, memantine if appropriate, caregiver support).
For moderate-stage age-related macular degeneration (specifically AREDS2 protocol): vitamin C 500 mg + α-tocopherol 400 IU + zinc 80 mg + copper 2 mg + lutein 10 mg + zeaxanthin 2 mg, all in the single AREDS2 formulation at standard dose. This is the specific tested combination and should not be modified. Do not use in current smokers (substitute the non-β-carotene AREDS2 formulation); do not over-interpret as benefit outside of AMD.
For premature infants at risk of hemolytic anemia: NICU protocols provide α-tocopherol 15-25 IU/kg/day in water-soluble formulation during the first weeks of life, reducing hemolysis and improving red cell function. Pediatric specialty territory.
For oxidative stress support in elderly or at-risk populations: α-tocopherol 100-400 IU/day as part of a broader antioxidant stack (vitamin C 500 mg, mixed carotenoids, selenium 100-200 μg). Evidence for clinical benefit is modest; biological plausibility is fair. Do not exceed 400 IU/day chronically without specific indication.
Advanced protocol (rare disease indications and specialty care). For ataxia with vitamin E deficiency (AVED, α-TTP / TTPA mutations): high-dose α-tocopherol 800-2000 mg/day (approximately 1,200-3,000 IU/day of natural RRR form) oral in divided doses. Supplement for life. Monitor serum α-tocopherol, neurologic progression, and coagulation parameters. Disease progression halts or slows meaningfully with adequate tissue α-tocopherol levels; some recovery of neurologic function is possible with early treatment. Specialist neurogenetics care.
For abetalipoproteinemia (MTP mutations): oral α-tocopherol 100-200 mg/kg/day in water-soluble TPGS formulation, along with other fat-soluble vitamin replacement. Retinal and neurologic function can be preserved with adequate supplementation. Specialist care.
For severe cholestatic liver disease (progressive familial intrahepatic cholestasis, biliary atresia): TPGS α-tocopherol 15-25 IU/kg/day; adjust to serum α-tocopherol target. Along with fat-soluble vitamin A, D, K replacement. Hepatology specialty.
For cystic fibrosis across the lifespan: α-tocopherol supplementation per CF guidelines (typically 100-400 IU/day in adults, titrated to serum α-tocopherol levels). Part of the standard ADEK replacement strategy.
For skin and wound healing — honest assessment. Topical α-tocopheryl acetate for scar prevention has not been supported by controlled trials (Baumann 1999); about 1/3 of users developed contact dermatitis that worsened cosmetic outcomes. Systemic high-dose vitamin E for post-surgical wound healing has mixed-to-negative trial data. Do not over-promise to patients seeking scar optimization.
Stop rules (all vitamin E contexts). Any new GI bleeding (hematemesis, melena, hematochezia) or prolonged unexplained bleeding should prompt immediate discontinuation. New heart failure symptoms in high-risk CV population (HOPE-TOO signal) warrant discontinuation and cardiology evaluation. Elevated INR (if on warfarin) warrants dose reduction or discontinuation with anticoagulation clinic guidance. Unexplained hepatic enzyme elevation >3× ULN on very-high-dose therapy warrants dose reduction. New cancer diagnosis in patient on chronic high-dose α-tocopherol — discuss implications with oncology; avoid reflexive continuation.
Commonly Stacked With
Vitamin E stacks strategically within the fat-soluble vitamin family and with nutrients that support its antioxidant recycling chemistry. Thoughtful combinations amplify mechanism; reflexive stacking can introduce harm signals.
Fat-soluble vitamin core (A, D, E, K). Vitamin E at dietary adequacy (15 mg/day) paired with vitamin A at RDA (700-900 μg RAE), vitamin D3 at 2,000-4,000 IU/day, and vitamin K2 at 100-180 μg MK-7 forms the standard ADEK chassis. For cystic fibrosis and chronic cholestatic malabsorption, pre-formulated ADEK supplements at elevated doses (titrated to serum levels) are standard. High-dose α-tocopherol (>400 IU/day) blunts vitamin K-dependent carboxylation; if a patient needs high-dose vitamin E for a defined indication, vitamin K2 co-supplementation at 180-360 μg/day helps maintain γ-carboxylation adequacy.
Vitamin E + vitamin C — the classic recycling pair. Ascorbate at the aqueous-lipid interface reduces the α-tocopheroxyl radical back to α-tocopherol. Without adequate vitamin C, α-tocopherol's chain-breaking antioxidant function degrades from recycling to stoichiometric. For general antioxidant support, 200-500 mg vitamin C paired with 15-60 mg α-tocopherol is biologically sensible. Megadose combinations (vitamin C 1-2 g + vitamin E 400-800 IU) have been tested in various outcome trials without clear benefit; don't use stacking to justify doses that exceed evidence-based recommendations for each component.
Vitamin E + CoQ10. Ubiquinol regenerates α-tocopherol within the lipid bilayer. 100-200 mg ubiquinol + 100-200 IU α-tocopherol is a coherent "membrane antioxidant" stack. In statin-associated muscle symptoms or in mitochondrial support protocols, this pair makes sense alongside magnesium, alpha-lipoic acid, and L-carnitine.
Vitamin E + selenium. Selenium-dependent glutathione peroxidase 4 (GPX4) reduces lipid hydroperoxides (LOOH) — the products generated when vitamin E intercepts lipid peroxyl radicals. Without GPX4, LOOH accumulates and can decompose to further radicals. Selenium 100-200 μg/day paired with α-tocopherol at physiologic doses is complementary. The SELECT trial tested this combination (selenium 200 μg + α-tocopherol 400 IU) and found no benefit; that does not refute the mechanistic logic but does caution against expecting dramatic benefit from this pair in otherwise healthy men.
Mixed tocopherols + tocotrienols. Isolated α-tocopherol suppresses serum γ-tocopherol. For users taking supplemental vitamin E, a mixed-tocopherol or mixed-tocopherol-and-tocotrienol product provides more physiologic diversity than isolated α-tocopherol. Annatto-derived tocotrienols (approximately 90% δ-tocotrienol and 10% γ-tocotrienol) are used at 150-300 mg/day for LDL support or cardiovascular purposes; palm-derived mixed tocotrienols are similar. If choosing α-tocopherol alone, lower doses (60-200 IU) are preferred to minimize γ-tocopherol displacement.
Vitamin E + omega-3 fatty acids. Omega-3 fatty acids EPA+DHA are PUFAs that are vulnerable to peroxidation; pairing with antioxidant α-tocopherol (and vitamin C and selenium) protects them. Most high-quality fish oil formulations include natural α-tocopherol as antioxidant preservative. Stack logic: 1-2 g EPA+DHA + 30-60 mg α-tocopherol + 100-200 mg vitamin C + 50-100 μg selenium provides comprehensive PUFA protection. High-dose fish oil (>3 g/day) increases peroxidation substrate and should be paired with adequate antioxidant backup.
Vitamin E in NASH protocol. For biopsy-proven NASH in non-diabetic adults: α-tocopherol 800 IU/day is the evidence-based dose (Sanyal 2010 PIVENS). Consider pairing with berberine 500 mg BID if metabolic syndrome features are present, omega-3 fatty acids 2-4 g EPA+DHA/day, and standard lifestyle intervention (weight loss, Mediterranean diet). Monitor LFTs at 3-6 month intervals and plan for eventual discontinuation or dose reduction given long-term α-tocopherol safety signals.
Vitamin E in Alzheimer's protocol. For mild-to-moderate AD: α-tocopherol 2,000 IU/day (Dysken 2014 TEAM-AD, PMID 24381967). Consider vitamin K2 180-360 μg/day MK-7 to offset γ-carboxylation impairment, CoQ10 200-400 mg/day for additional mitochondrial support, omega-3 fatty acids 2 g/day DHA-enriched. Avoid stacking with anticoagulants without careful risk/benefit and INR monitoring.
AREDS and AREDS2 for moderate AMD. The evidence-based combination: vitamin C 500 mg + α-tocopherol 400 IU + zinc 80 mg + copper 2 mg (AREDS original), with AREDS2 replacing β-carotene with lutein 10 mg + zeaxanthin 2 mg. This is the specific tested combination and should not be modified without informed rationale.
Immune support stack for elderly. Modest α-tocopherol 100-200 IU/day + vitamin C 500 mg + zinc 15-30 mg + vitamin D3 2,000 IU is a reasonable cold-season immune chassis for older adults. Evidence base for each component is modest but converging; combination trials have shown reduced URI incidence (Meydani 2004 for vitamin E specifically).
Avoid stacking high-dose vitamin E with certain chemotherapy. Antioxidants including high-dose α-tocopherol may theoretically interfere with ROS-dependent chemotherapy mechanisms (anthracyclines like doxorubicin, platinum agents, some kinase inhibitors). Consult oncology before combining; avoid reflexive stacking.
Avoid stacking α-tocopherol megadose with prescription retinoids (acitretin, isotretinoin, bexarotene). Theoretical RXR crosstalk and additive hepatotoxic concerns; no strong trial evidence of harm but reasonable caution.
Topical vitamin E. Topical α-tocopherol in cosmetic or dermatology products is generally well-tolerated but evidence for efficacy in scar prevention or wound healing is poor (Baumann 1999). Allergic contact dermatitis occurs in a small minority. Topical vitamin E + silicone gel sheeting combinations have been tested in scar management with inconsistent results.
TPGS (tocopheryl polyethylene glycol succinate) as solubilizer. TPGS is a water-miscible α-tocopherol prodrug used as a pharmaceutical excipient for improving solubility and absorption of lipophilic drugs (cyclosporine in Neoral formulation). Not typically used as a vitamin E supplement per se, but notable for its ability to enhance absorption of various poorly-soluble compounds. If a patient is receiving cyclosporine in Neoral, they are getting some vitamin E via TPGS.
Side Effects & Safety
Contraindications
Vitamin E has a manageable safety profile at dietary and modest supplementation doses but has clinically meaningful contraindications and precautions at high doses and in specific populations. Absolute contraindications: - Active bleeding disorder (hemophilia, severe von Willebrand disease, platelet dysfunction disorders): avoid supplementation above the RDA due to additive bleeding risk. - Warfarin or other vitamin K antagonist therapy with target INR, without close monitoring: do not supplement vitamin E above the RDA. If high-dose vitamin E is required for a defined indication (NASH, AD), close anticoagulation clinic monitoring with INR adjustment is mandatory. - Scheduled elective surgery within 1-2 weeks: discontinue vitamin E ≥400 IU/day 1-2 weeks pre-operatively due to bleeding risk. - Known hypersensitivity to tocopherol excipients or formulation ingredients. Rare but documented. - Premature infants receiving iron supplementation without appropriate vitamin E cover: vitamin E deficiency in premature infants on iron can produce hemolytic anemia; standard NICU practice provides adequate vitamin E cover. Relative precautions: - Current smoking with chronic high-dose α-tocopherol (≥400 IU/day) supplementation: SELECT trial showed increased prostate cancer risk in men ≥50 years with 7-year follow-up; Finnish ATBC smokers had non-significant hemorrhagic stroke signal. Use caution; prefer dietary sources. - Men ≥50 years without specific indication for high-dose α-tocopherol: SELECT prostate cancer signal argues against chronic supplementation at 400 IU/day. - Heart failure (especially with prior MI or diabetes history): HOPE-TOO signal of increased heart failure hospitalization at 400 IU/day. - Concurrent antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel) or anticoagulation: additive bleeding risk. - History of recurrent GI bleeding or peptic ulcer disease: caution with high-dose supplementation. - Pregnancy (especially hypertensive disorders): avoid supplementation above RDA; VIP trial did not support benefit for preeclampsia prevention and showed increased gestational hypertension in some subgroups. - Known CYP4F2 slow-metabolizer variants (rs2108622 homozygotes, common in some populations): enhanced α-tocopherol retention at standard doses; lower supplementation doses may be adequate, and high-dose supplementation may produce higher tissue levels than expected. - Chronic kidney disease advanced stages (stage 4-5, dialysis): no specific dose adjustment for α-tocopherol but monitor bleeding risk given frequent concurrent antiplatelet/anticoagulant use in this population. - Liver disease without clear NASH indication: avoid empirical high-dose α-tocopherol; limit to documented NASH per specialist. - Chemotherapy with ROS-dependent mechanisms (anthracyclines, platinums, some kinase inhibitors): theoretical antioxidant interference; consult oncology before high-dose supplementation. Drug-drug interactions: - Warfarin + α-tocopherol ≥400 IU/day: elevated INR risk, bleeding complications. - DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) + high-dose vitamin E: theoretical additive bleeding risk. - Antiplatelet drugs + high-dose vitamin E: additive bleeding risk. - Orlistat + vitamin E: reduced absorption, space by 2 hours. - Bile acid sequestrants + vitamin E: reduced absorption, space by 4 hours. - Mineral oil laxative + vitamin E: reduced absorption. - Anti-epileptic drugs (phenytoin, carbamazepine, phenobarbital) + vitamin E: may reduce vitamin E status; monitor. - Cyclosporine formulated in TPGS (Neoral): TPGS increases cyclosporine bioavailability; dose adjustment as per transplant practice. - Chemotherapy + high-dose vitamin E: theoretical ROS-mechanism interference. Supplement-supplement considerations: - [Vitamin K2](/compound/vitamin-k2) + high-dose vitamin E: complementary; K2 supplementation helps offset γ-carboxylation impairment from α-tocopherol megadose. - [Vitamin C](/compound/vitamin-c) + vitamin E: complementary antioxidant recycling; generally beneficial. - [Selenium](/compound/selenium) + vitamin E: mechanistically complementary (GPX4 + chain-breaking); SELECT trial did not show additive benefit in a healthy male population and showed harm in the α-tocopherol arm. - [CoQ10](/compound/coq10) + vitamin E: complementary membrane antioxidant recycling. - [Iron](/compound/iron) + vitamin E: potential pro-oxidant interaction with iron catalyzing vitamin E oxidation; generally not harmful but can be formulation-optimized. - [Omega-3 fatty acids](/compound/omega-3-fatty-acids) + vitamin E: complementary (antioxidant protection of PUFAs); most fish oil products include α-tocopherol as preservative. Pediatric considerations. Premature infants require NICU vitamin E cover to prevent hemolytic anemia. Older infants and children: follow age-appropriate RDA via dietary adequacy or pediatric multivitamin. High-dose supplementation in pediatric populations is specialist territory (CF, cholestatic disease, AVED). Pregnancy. Standard RDA intake is safe and necessary. High-dose supplementation has not shown pregnancy benefit and carries some potential for gestational hypertension or bleeding risk. Avoid supplementation above RDA without specific indication. Elderly. Immune support at 100-200 IU/day is reasonable. Avoid ≥400 IU/day chronically without indication due to Miller meta-analysis mortality signal. SELECT prostate cancer signal applies particularly to men ≥50 years. Attention to bleeding risk given frequent concurrent anticoagulant use. Post-surgical and post-procedural. Discontinue ≥400 IU/day vitamin E 1-2 weeks before elective procedures; resume 1-2 weeks post-op per surgeon guidance. Skin procedures (laser, chemical peel, dermabrasion). Topical vitamin E has no documented efficacy for scar prevention and may cause contact dermatitis worsening cosmetic outcomes. Systemic high-dose vitamin E for post-procedural healing has mixed-to-negative trial data. Avoid recommending except as part of broader dermatology-approved regimen. Overall, vitamin E at RDA (15 mg/day) is safe and necessary. Modest supplementation (100-200 IU/day) is reasonable for specific populations. High-dose supplementation (≥400 IU/day chronic) should be reserved for defined indications (NASH, AD, AVED, abetalipoproteinemia, AREDS2 as part of the specific tested combination) with appropriate specialist supervision and bleeding risk assessment.
Additional Notes
Vitamin E dosing requires attention to form (natural RRR- vs. synthetic all-rac-), unit conversion (IU vs. mg α-TE), isomer profile (isolated α-tocopherol vs. mixed tocopherols vs. tocotrienols), and indication-specific dosing.
Unit conventions. 1 mg RRR-α-tocopherol = 1 α-tocopherol equivalent (α-TE) = 1.49 IU (natural). 1 mg all-rac-α-tocopherol (synthetic dl-) = 0.74 α-TE = 1 IU (synthetic). So a "400 IU" label on a synthetic all-rac-α-tocopheryl acetate supplement provides 400 mg of the racemic mixture and approximately 180 mg of biologically active RRR-equivalent, whereas "400 IU" of natural d-α-tocopheryl acetate provides approximately 268 mg of the acetate ester and nearly all of its mass as biologically active RRR-α-tocopherol after ester hydrolysis. Label reading is important.
Tocopheryl esters (acetate, succinate, nicotinate). These are the common supplement forms, more stable against oxidation during storage than free α-tocopherol. Intestinal esterases hydrolyze them to free α-tocopherol before or during absorption; bioavailability is comparable to free α-tocopherol with adequate dietary fat. Tocopheryl succinate has been studied for some cancer-related indications based on in vitro data but does not have clear human outcome evidence.
RDA and AI. Adults 14+: 15 mg α-TE/day (approximately 22 IU RRR- or 30 IU all-rac-). Pregnancy: 15 mg (same as non-pregnant). Lactation: 19 mg. Pediatric: 4 mg (0-6 months), 5 mg (7-12 months), 6 mg (1-3 years), 7 mg (4-8 years), 11 mg (9-13 years), 15 mg (14-18 years).
Tolerable upper intake level (synthetic supplemental α-tocopherol only): adults 1,000 mg α-TE/day (approximately 1,100 IU synthetic or 1,500 IU natural). Pediatric ULs: 200 mg (1-3 years), 300 mg (4-8 years), 600 mg (9-13 years), 800 mg (14-18 years). The UL was set based primarily on bleeding risk concerns and does not account for the Miller meta-analysis all-cause mortality signal or SELECT prostate cancer finding; contemporary clinical practice is often more conservative, preferring ≤400 IU/day chronic supplementation unless specific indication.
Typical supplementation doses by indication. Multivitamin: 15-30 IU α-tocopherol (synthetic dl- or natural d-). Elderly immune support: 100-200 IU natural RRR-α-tocopherol. AREDS2 formulation component: 400 IU α-tocopherol. NASH (PIVENS protocol): 800 IU natural RRR-α-tocopherol. Mild-to-moderate Alzheimer's (TEAM-AD protocol): 2,000 IU natural RRR-α-tocopherol. AVED: 800-2,000 mg/day. Cystic fibrosis: 100-400 IU depending on age and severity.
Mixed tocopherol and tocotrienol dosing. Mixed tocopherol products typically provide 50-400 mg/day with varying ratios of α, β, γ, and δ forms — total α-equivalents vary by product. Annatto tocotrienols (≈90% δ-T3, 10% γ-T3): 150-300 mg/day for lipid indications. Palm tocotrienol complex: 100-400 mg/day. Outcome evidence for these forms is less robust than for α-tocopherol, and dosing is less standardized.
Bioavailability. α-Tocopherol absorption requires dietary fat (minimum 3-5 g); take with a meal containing some fat. Absolute absorption fraction 20-70% depending on dose and meal context. Hepatic α-TTP-mediated selective retention means dose-response is non-linear — serum α-tocopherol plateaus at doses above about 400 IU/day as CYP4F2-mediated clearance increases. Higher doses achieve diminishing serum increases and increasing oxidative metabolite production. Tocotrienols have shorter tissue half-life due to α-TTP preference for α-tocopherol; they must be dosed multiple times daily for steady levels.
Timing. Take with meals containing dietary fat for best absorption. Split doses above 400 IU/day across the day for more sustained serum levels. No specific time-of-day requirement.
Interactions. Warfarin + α-tocopherol ≥400 IU/day: INR elevation risk, monitor closely, consider K2 supplementation. DOACs + high-dose vitamin E: theoretical bleeding risk. Antiplatelet drugs + high-dose vitamin E: additive bleeding risk. Orlistat + vitamin E: reduced absorption, space by 2 hours. Cholestyramine + vitamin E: reduced absorption. Statins at high doses + HATS trial (high-dose antioxidant combination): blunted HDL benefit of statin/niacin observed; modest signal, not applicable to typical use. Cyclosporine formulated in TPGS: increased cyclosporine bioavailability, dose adjustment. Chemotherapy (anthracyclines, platinums): theoretical ROS-mechanism interference, avoid high-dose supplementation without oncology guidance.
Special populations. Premature infants: NICU supplementation 15-25 IU/kg/day water-soluble. Fat malabsorption (CF, cholestasis, short bowel, bariatric): water-soluble TPGS form at specialist-directed doses. Dialysis: no dose adjustment standard. Pregnancy: stick to RDA; avoid supplementation above RDA without specific indication. AVED and abetalipoproteinemia: mega-dose replacement.
Monitoring. For high-dose therapy (≥800 IU/day), monitor serum α-tocopherol, INR if on warfarin, CBC and coagulation, LFTs at 6-12 month intervals, and periodic bleeding risk assessment. For general supplementation at dietary doses, no routine monitoring needed.
Frequently Asked Questions
What is the recommended Vitamin E dosage?
Dosage for Vitamin E varies by protocol. Consult a qualified healthcare provider.
How often should I take Vitamin E?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Vitamin E need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Vitamin E side effects?
Vitamin E has a reasonable safety profile at dietary and modest supplementation doses (up to the RDA of 15 mg/day for adults, or ~22 IU), but adverse effects become meaningful at high doses (≥400 IU/day chronic) and particularly in specific populations (patients on anticoagulants, patients with bleeding disorders, older smokers in the SELECT cohort-adjacent demographic). Mortality signal at high doses. Miller 2005 meta-analysis (PMID 15537682) of 19 RCTs found chronic vitamin E ≥400 IU/day was associated with a dose-dependent 4% increase in all-cause mortality vs. placebo. Subsequent Bjelakovic Cochrane analyses (PMID 22419320) found similar signals. Individual trials are often underpowered to detect this, but the pooled signal is consistent. Absolute risk increase is small but meaningful at population scale — and there is no corresponding benefit on CV events or total cancer to offset the risk. Prostate cancer — SELECT finding. α-tocopherol 400 IU/day increased prostate cancer incidence by 17% at 5-7 years post-randomization in the SELECT population (35,533 men ≥50-55 years, Klein 2011 JAMA). The signal emerged after trial discontinuation and during extended follow-up, suggesting a latency period. Mechanism proposed: α-tocopherol competition with γ-tocopherol tissue delivery, disruption of androgen signaling, or other nuclear receptor crosstalk. Clinical consequence: high-dose α-tocopherol supplementation in men ≥50 years is not recommended without a specific indication. Bleeding risk and anticoagulant interaction. α-tocopherol at doses ≥400 IU/day modestly inhibits vitamin K-dependent carboxylation of clotting factors II, VII, IX, X, and proteins C, S, Z (Booth 2004). Combined with warfarin, DOAC, or antiplatelet drugs, high-dose vitamin E increases bleeding risk. Clinically relevant bleeding events (GI bleeding, hemorrhagic stroke) have been reported with α-tocopherol megadoses in vulnerable populations. The ATBC trial showed a non-significant trend toward increased hemorrhagic stroke in α-tocopherol 50 mg/day arm in Finnish male smokers. For patients on any anticoagulant or dual antiplatelet therapy, vitamin E above the RDA should not be supplemented without monitoring of INR or bleeding risk assessment. Pre-operative discontinuation 1-2 weeks prior to elective surgery is standard practice for vitamin E ≥400 IU/day. Heart failure in high-risk patients. HOPE-TOO (PMID 15769967) found increased heart failure hospitalization in the vitamin E 400 IU/day arm among high-CV-risk patients. Mechanism unclear; consider avoidance in heart failure patients. Upper intake level. The Institute of Medicine has set a tolerable upper intake level of 1,000 mg/day (1,500 IU of RRR-α-tocopherol or 1,100 IU of synthetic dl-α-tocopherol) of supplemental α-tocopherol in adults, based primarily on the bleeding risk concern. This UL does not account for the SELECT signal or Miller meta-analysis findings; contemporary clinical practice tends to be more conservative, advising ≤400 IU/day chronic unless specific indication. GI effects. High-dose α-tocopherol (≥800 IU/day) occasionally causes nausea, diarrhea, abdominal cramping, or loose stools. These are usually mild and dose-reducible. Rare hepatic enzyme elevations reported at doses ≥1,000 IU/day; monitor LFTs in long-term very-high-dose therapy. Fatigue, weakness, blurred vision at very high doses. Rare, dose-related, reversible with discontinuation. Skin rash. Rare allergic dermatitis to α-tocopheryl acetate or other vitamin E supplement excipients has been reported. Topical vitamin E is a recognized cause of contact dermatitis. Drug-drug and drug-nutrient interactions. Warfarin + vitamin E ≥400 IU/day: elevated INR risk, monitor closely. DOACs + vitamin E: theoretical increased bleeding risk. Antiplatelet drugs (aspirin, clopidogrel) + vitamin E: additive bleeding risk. Statins + vitamin E: no significant interaction at modest doses; very high-dose vitamin E in some lipid trials appeared to blunt the HDL benefit of statin/niacin combination (HATS trial ancillary finding). Cyclosporine + vitamin E (as TPGS): TPGS can increase cyclosporine absorption; dose adjustment may be needed. Chemotherapy + high-dose vitamin E: theoretical concern that antioxidants could interfere with ROS-dependent chemotherapy mechanisms (anthracyclines, platinums); consult oncology before combining. Pregnancy and lactation. Vitamin E at dietary RDA (15 mg/day, pregnancy RDA unchanged) is safe and necessary. High-dose α-tocopherol supplementation (>200 IU/day) during pregnancy has not been shown beneficial for preventing preeclampsia despite earlier theoretical promise (VIP trial), and some trials have shown increased gestational hypertension. Avoid supplementation above RDA during pregnancy without specific indication. Pediatric. Vitamin E deficiency in premature infants causes hemolytic anemia; prophylactic vitamin E supplementation is standard in NICU practice. Pediatric RDA: 4 mg (0-6 months), 5 mg (7-12 months), 6 mg (1-3 years), 7 mg (4-8 years), 11 mg (9-13 years), 15 mg (14-18 years). ULs are age-adjusted and substantially lower than adult (200 mg for 1-3 years, 300 mg for 4-8 years, 600 mg for 9-13 years, 800 mg for 14-18 years). Renal impairment. Vitamin E is fat-soluble and primarily biliary-cleared via CEHCs in urine; renal impairment does not dramatically alter pharmacokinetics at standard doses. In dialysis patients, vitamin E has been tested in several small trials for oxidative stress and CV outcomes with mixed results; not standard practice. Hepatic impairment. Bile acid dependence for absorption means severe cholestasis can functionally reduce vitamin E status; replacement with water-soluble α-tocopherol polyethylene glycol succinate (TPGS) is used in pediatric cholestatic liver disease and is effective. Smoking population. ATBC found α-tocopherol 50 mg/day safe without CV harm in Finnish male smokers and a possible (probably chance) prostate cancer benefit. SELECT found harm at 400 IU/day; the smoking population was small in SELECT. High-dose α-tocopherol supplementation in smokers should be approached cautiously given the similar mechanism concerns as β-carotene in ATBC/CARET. Pre-operative considerations. Discontinue vitamin E ≥400 IU/day 1-2 weeks before elective surgery due to bleeding risk. This is standard practice in most surgical specialties. Topical vitamin E. Topical α-tocopherol in cosmetic and OTC skincare products is generally safe; rare allergic contact dermatitis is possible. Topical vitamin E for scar improvement has not been proven effective in controlled trials (Baumann 1999) and is sometimes associated with contact dermatitis that can worsen cosmetic outcomes — a classic "popular but unsupported" dermatology intervention. Overall, vitamin E at RDA doses (15 mg/day, approximately 22 IU) is safe and essential. Supplementation at 100-200 IU/day for specific indications (modest antioxidant support, immune function in elderly) is reasonable. Chronic supplementation at ≥400 IU/day in otherwise healthy adults is discouraged by the aggregate evidence base. Therapeutic doses (800-2,000 IU/day) for NASH, AD, AVED are appropriate under specialist supervision with attention to bleeding risk.
Where can I buy Vitamin E?
Visit our vendor directory to find trusted sources for Vitamin E.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
